Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
130.67
-0.78 (-0.60%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Inhibrx Biosciences Employees
As of December 31, 2025, Inhibrx Biosciences had 110 total employees, including 109 full-time and 1 part-time employees. The number of employees decreased by 51 or -31.68% compared to the previous year.
Employees
110
Change (1Y)
-51
Growth (1Y)
-31.68%
Revenue / Employee
$11,818
Profits / Employee
-$1,273,227
Market Cap
1.91B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 110 | -51 | -31.68% |
| Dec 31, 2024 | 161 | -11 | -6.40% |
| Dec 31, 2023 | 172 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Galapagos NV | 558 |
| Vericel | 398 |
| Syndax Pharmaceuticals | 298 |
| Harmony Biosciences Holdings | 293 |
| Capricor Therapeutics | 231 |
| Pharvaris | 129 |
| AnaptysBio | 104 |
| Taysha Gene Therapies | 99 |
INBX News
- 6 days ago - Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges - Benzinga
- 7 days ago - Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
- 7 days ago - Inhibrx Biosciences Transcript: Study update - Transcripts
- 7 days ago - Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer - PRNewsWire
- 8 days ago - Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer - PRNewsWire
- 5 weeks ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results - PRNewsWire
- 2 months ago - Inhibrx Announces Participation in Upcoming Scientific Conference - PRNewsWire
- 3 months ago - These 20 stocks are strong choices for momentum investors - Market Watch